SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Illumina, Inc. – ‘8-K’ for 9/6/22

On:  Tuesday, 9/6/22, at 5:13pm ET   ·   For:  9/6/22   ·   Accession #:  950157-22-997   ·   File #:  1-35406

Previous ‘8-K’:  ‘8-K’ on / for 8/11/22   ·   Next:  ‘8-K’ on 9/16/22 for 9/14/22   ·   Latest:  ‘8-K’ on / for 11/14/22   ·   1 Reference:  By:  Illumina, Inc. – ‘424B2’ on 11/29/22

Magnifying glass tilted right emoji
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 9/06/22  Illumina, Inc.                    8-K:8,9     9/06/22   11:185K                                   Cravath Swaine & … 01/FA

Current Report   —   Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     31K 
 2: EX-99.1     Press Release                                       HTML     17K 
 6: R1          Document and Entity Information                     HTML     45K 
 9: XML         IDEA XML File -- Filing Summary                      XML     12K 
 7: XML         XBRL Instance -- form8-k_htm                         XML     15K 
 8: EXCEL       IDEA Workbook of Financial Reports                  XLSX      8K 
 4: EX-101.LAB  XBRL Labels -- ilmn-20220906_lab                     XML     63K 
 5: EX-101.PRE  XBRL Presentations -- ilmn-20220906_pre              XML     46K 
 3: EX-101.SCH  XBRL Schema -- ilmn-20220906                         XSD     14K 
10: JSON        XBRL Instance as JSON Data -- MetaLinks               13±    19K 
11: ZIP         XBRL Zipped Folder -- 0000950157-22-000997-xbrl      Zip     25K 

‘8-K’   —   Current Report

This is an HTML Document rendered as filed.  [ Alternative Formats ]

 iX:   C: 
 i false i 000111080300011108032022-09-062022-09-06

Washington, D.C. 20549

Form  i 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  i September 6, 2022


 i Illumina, Inc.
(Exact name of registrant as specified in its charter)

 i 001-35406
(Commission File Number)

 i Delaware
(State or other jurisdiction of incorporation)
 i 33-0804655
(I.R.S. Employer Identification No.)

 i 5200 Illumina Way,  i San Diego,  i CA  i 92122
(Address of principal executive offices) (Zip code)

( i 858)  i 202-4500
(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 i  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 i  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 i  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 i  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
 i Common Stock, $0.01 par value
Trading Symbol(s)
Name of each exchange on which registered
 i The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  i 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13a of the Exchange Act. ☐


Item 8.01.  Other Events.

As previously disclosed, on August 18, 2021, pursuant to the Agreement and Plan of Merger, dated as of September 20, 2020, as amended, by and among Illumina, Inc., a Delaware corporation (“Illumina”), GRAIL, Inc., a Delaware corporation (together with any successor entity, “GRAIL”), and the other parties thereto, Illumina completed its acquisition of GRAIL, Inc. (the “Acquisition”).

Also as previously disclosed, on April 19, 2021, the European Commission accepted a request for referral of the Acquisition (the “Referral”) for European Union merger review under Article 22(1) of Council Regulation (EC) No 139/2004 (the “EU Merger Regulation”), which had been submitted by a Member State of the European Union.

Also as previously disclosed, on April 29, 2021, Illumina filed an action in the General Court of the European Union (the “EU General Court”) asking for annulment of the European Commission’s decision asserting jurisdiction to review the Acquisition under Article 22 of the EU Merger Regulation. On July 13, 2022, the EU General Court ruled that the European Commission has jurisdiction to review the Acquisition under Article 22(1) of the EU Merger Regulation. Illumina disagrees with the EU General Court’s decision and intends to file its appeal to the Court of Justice of the European Union.

On September 6, 2022, the European Commission announced that it had completed its Phase II review of the Acquisition and adopted a final decision (the “Prohibition Decision”), which found that, in its view, Illumina’s acquisition of GRAIL was incompatible with the internal market in Europe because it results in a significant impediment to effective competition.  Public statements made by the European Commission in connection with the Prohibition Decision indicate that a subsequent decision is likely to be adopted by the European Commission that will order Illumina to divest GRAIL (an “EC Divestment Decision”).  Neither the Prohibition Decision nor such public statements indicate when any such EC Divestment Decision may be adopted.

Illumina intends to appeal the Prohibition Decision to the EU General Court. Illumina also intends to appeal any EC Divestment Decision (if and when adopted by the European Commission) and, if necessary, to seek interim relief suspending the divestment of GRAIL until the final determination of these appeals.

The Prohibition Decision and an EC Divestment Decision, and any order or decision by the U.S. Federal Trade Commission pursuant to which Illumina is required to divest GRAIL (together with an EC Divestment Decision, a “Divestment Decision”), if implemented once final and non-appealable or during the pendency of the applicable appeals proceedings, and Illumina’s obligations pursuant thereto, will impose significant costs and additional liabilities on Illumina, including significant advisory fees and additional expenses, and may result in loss of revenue and other adverse effects on Illumina’s business, financial condition and results of operations. Such adverse effects could include Illumina being required to divest GRAIL on terms that are materially worse than the terms on which Illumina acquired GRAIL. For example, Illumina will not be able to, in a sale of GRAIL, effect such sale in a non-taxable transaction and so will incur significant tax liabilities attributable to the recognition of taxable gain equal to the difference between (i) the fair market value of any consideration received and (ii) Illumina’s tax basis in GRAIL (which tax basis is currently estimated to be approximately $700 million). Furthermore, the Prohibition Decision and the implementation of a Divestment Decision could divert management’s attention and company resources away from existing operations and other opportunities that may have been beneficial to Illumina, any or all of which, individually or in the aggregate, could have a material adverse effect on Illumina’s business, financial condition and results of operation. Illumina cannot predict what other adverse consequences to, among other things, its reputation, its relationships with governmental or regulatory authorities or its ability to successfully complete future transactions may result.

On September 6, 2022, Illumina issued a press release addressing the Prohibition Decision. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

Cautionary Notes on Forward-Looking Statements

This communication contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” “will,” “would,” “may,” “target,” similar expressions and variations or negatives of these words. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the effects of the consummation of the transaction and the anticipated benefits thereof. These and other forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forward-looking statements. Important risk factors that may cause such a difference include, but are not limited to: (i) the terms and conditions of any required divestiture of GRAIL, and the timing of and the risks, costs and business disruptions (including the diversion of management’s attention) associated with any such divestiture, the announcement, pendency or implementation thereof or any associated legal or regulatory proceedings or obligations, and other uncertainties related to Illumina’s compliance (or ability to comply) with a Divestment Decision, which may adversely affect Illumina and its business, including current plans and operations; (ii) the possibility of other adverse consequences to, among other things, Illumina’s reputation, its relationships with governmental or regulatory authorities or its ability to successfully complete future acquisitions and/or divestitures as a result of the Acquisition, the Prohibition Decision or a Divestment Decision; (iii) the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, dis-synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of Illumina’s business following or in connection with any divestiture of GRAIL; (iv) potential adverse reactions or changes to business relationships or our ability to attract and retain employees resulting from the announcement, pendency or implementation of the Decisions and/or legal, regulatory and other proceedings related thereto; (v) any negative effects of the announcement, pendency or implementation of the Prohibition Decision or a Divestment Decision and/or of any divestiture of GRAIL on the market price of Illumina’s common stock and on Illumina’s operating results; (vi) risks associated with third-party contracts or other agreements containing provisions that might be implicated by any divestiture of GRAIL, including Illumina’s obligations with respect to certain GRAIL contingent value rights and the risk that Illumina will be unable to fully discharge such obligations in connection with a divestiture of GRAIL; (vii) the risk that Illumina will be unable to recover the costs and/or realize the economic benefits associated with its efforts to develop and commercialize GRAIL’s products, including Galleri, the cancer screening test developed by GRAIL; (viii) the risk that Illumina’s appeals of the Prohibition Decision or a Divestment Decision and the EU General Court’s ruling on the European Commission’s jurisdiction to review the Acquisition and impose any decisions with respect thereto are unsuccessful and of other negative outcomes of legal, regulatory and other proceedings related thereto; (ix) the risk of adverse effects resulting from additional potential litigation associated with the Acquisition; (x) the other risks described in Illumina’s most recent annual reports on Form 10-K and quarterly reports on Form 10-Q and (xi) management’s response to any of the aforementioned factors.

While the list of factors presented here is, and the list of factors presented in Illumina’s public filings are, considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on Illumina’s financial condition, results of operations, credit rating or liquidity. Illumina does not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

Item 9.01.  Financial Statements and Exhibits.

(d) Exhibits.




Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 6, 2022

Charles E. Dadswell
Senior Vice President, General Counsel and Secretary

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
Filed on / For Period end:9/6/22
8/18/214,  8-K,  8-K/A
4/19/213,  8-K
 List all Filings 

1 Subsequent Filing that References this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/29/22  Illumina, Inc.                    424B2                  1:500K                                   Donnelley … Solutions/FA
Filing Submission 0000950157-22-000997   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2022 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Wed., Nov. 30, 12:38:18.1pm ET